Maligne Lymphome im Erwachsenenalter

Schlüsselwörter

B-Zell-Lymphome - T-Zell-Lymphome - follikuläre Lymphome - Mantelzell-Lymphome

Key words

B-cell lymphoma - T-cell lymphoma - follicular lymphome - mantle-cell lymphoma

Literatur

• 1 A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.  N Engl J Med. 1993;  329 987-994
• 2 Bonnet C, Fillet G, Mounier N. et al . CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients.  J Clin Oncol. 2007;  25 787-792
• 3 Bookman M A, Lardelli P, Jaffe E S, Duffey P L, Longo D L. Lymphocytic lymphoma of intermediate differentiation: morphologic, immunophenotypic, and prognostic factors.  J Natl Cancer Inst. 1990;  82 742-748
• 4 Brenner D J, Hall E J. Computed tomography – an increasing source of radiation exposure.  N Engl J Med. 2007;  357 2277-2284
• 5 Coiffier B, Lepage E, Briere J. et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
• 6 Colwill R, Crump M, Couture F. et al . Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation.  J Clin Oncol. 1995;  13 396-402
• 7 Dreyling M, Lenz G, Hoster E. et al . Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.  Blood. 2005;  105 2677-2684
• 8 Dreyling M. on behalf of the EGWG . Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.  Ann Oncol. 2008;  19 ii77-78
• 9 El Gnaoui T, Dupuis J, Belhadj K. et al . Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.  Ann Oncol. 2007;  18 1363-1368
• 10 Elis A, Blickstein D, Klein O. et al . Detection of relapse in non-Hodgkin’s lymphoma: role of routine follow-up studies.  Am J Hematol. 2002;  69 41-44
• 11 Fischbach W, Dragosics B, Kolve-Goebeler M E. et al . Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group.  Gastroenterology. 2000;  119 1191-1202
• 12 Fischbach W, Goebeler M E, Ruskone-Fourmestraux A. et al . Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series.  Gut. 2007;  56 1685-1687
• 13 Forstpointner R, Dreyling M, Repp R. et al . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas.  Blood. 2004;  104 3064-3071
• 14 Forstpointner R, Unterhalt M, Dreyling M. et al .Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas. Blood 2006 108: 4003-4008
• 15 Fridrik M A, Hausmaninger H, Lang A. et al .Low risk patients with aggressive non-Hodgkin’s lymphoma have superior suvival with dose density chemotherapy. ASCO Annual Meeting 2003 abstract 2306
• 16 Gallamini A, Stelitano C, Calvi R. et al . Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.  Blood. 2004;  103 2474-2479
• 17 Geisler C H, Elonen E, Kolstad A. et al . Mantle cell lymphoma can be cured by intensive immunochemotherapy with in-vivo purged stem-cell support. Final Report of the Nordic Lymphoma Group MCL2 Study.  ASH Annual Meeting Abstracts. 2007;  110 LB1
• 18 Guppy A E, Tebbutt N C, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma.  Leuk Lymphoma. 2003;  44 123-125
• 19 Haas R LM, Poortmans P, de Jong D. et al . High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.  J Clin Oncol. 2003;  21 2474-2480
• 20 Habermann T M, Weller E A, Morrison V A. et al .Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 JCO.2005.2005.1003
• 21 Hagenbeek A, Bischof-Delaloye A, Radford J A. et al . 90Y-Ibritumomab Tiuxetan (Zevalin(R)) Consolidation of first remission in advanced stage follicular non-Hodgkin’s lymphoma: First results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 patients.  ASH Annual Meeting Abstracts. 2007;  110 643
• 22 Harris N L, Jaffe E S, Diebold J. et al . World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.  J Clin Oncol. 1999;  17 3835-3849
• 23 Hiddemann W, Kneba M, Dreyling M. et al . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone.  Blood. 2005;  106 3725-3732
• 24 Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.  N Engl J Med. 1984;  311 1471-1475
• 25 Hoster E, Dreyling M, Klapper W. et al . A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.  Blood. 2008;  111 558-565
• 26 Kaufmann H, Raderer M, Wohrer S. et al . Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.  Blood. 2004;  104 2269-2271
• 27 Kewalramani T, Zelenetz A D. et al . Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.  Blood. 2004;  103 3684-3688
• 28 Le Gouill S, Milpied N, Buzyn A. et al . Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults.  J Clin Oncol. 2008;  26 2264-2271
• 29 Leitch H A, Gascoyne R D, Chhanabhai M. et al . Limited-stage mantle-cell lymphoma.  Ann Oncol. 2003;  14 1555-1561
• 30 Liedtke M, Hamlin P A, Moskowitz C H, Zelenetz A D. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse.  Ann Oncol. 2006;  17 909-913
• 31 Mac Manus M P, Hoppe R T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? .  J Clin Oncol. 1996;  14 1282-1290
• 32 Marcus R, Imrie K, Belch A. et al . CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.  Blood. 2005;  105 1417-1423
• 33 McKelvey E M, Gottlieb J A, Wilson H E. et al . Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.  Cancer. 1976;  38 1484-1493
• 34 Meusers P, Engelhard M, Bartels H. et al . Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis.  Hematol Oncol. 1989;  7 365-380
• 35 Miller T P, Dahlberg S, Cassady J R. et al . Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma.  N Engl J Med. 1998;  339 21-26
• 36 Moskowitz C H, Bertino J R, Glassman J R. et al . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma.  J Clin Oncol. 1999;  17 3776-3785
• 37 Neubauer A, Thiede C, Morgner A. et al . Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma.  J Natl Cancer Inst. 1997;  89 1350-1355
• 38 Pfreundschuh M, Trumper L, Kloess M. et al . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas.  Blood. 2004;  104 634-641
• 39 Pfreundschuh M, Trumper L, Osterborg A. et al . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma.  Lancet Oncol. 2006;  7 379-391
• 40 Philip T, Guglielmi C, Hagenbeek A. et al . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.  N Engl J Med. 1995;  333 1540-1545
• 41 Reyes F, Lepage E, Ganem G. et al . ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.  N Engl J Med. 2005;  352 1197-1205
• 42 Rohatiner A ZS, Gregory W M. et al . Meta-analysis to evaluate the role of interferon in follicular lymphoma.  J Clin Oncol. 2005;  23 2215-2223
• 43 Romaguera J E, Fayad L, Rodriguez M A. et al . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.  J Clin Oncol. 2005;  23 7013-7023
• 44 Rummel M J, von Gruenhagen U, Niederle N. et al . Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas – first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).  ASH Annual Meeting Abstracts. 2007;  110 385
• 45 Savage K J, Harris N L, Vose J M. et al .ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008 111: 5496-5504
• 46 Schechter N R, Portlock C S, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.  J Clin Oncol. 1998;  16 1916-1921
• 47 Schouten H C, Qian W, Kvaloy S. et al . High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma.  J Clin Oncol. 2003;  21 3918-3927
• 48 Schulz H, Bohlius J F, Trelle S. et al . Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma.   J Natl Cancer Inst. 2007;  99 706-714
• 49 Smith M R, Zhang L, Gordon L I. et al . Phase II study of R-CHOP followed by 90Y-Ibritumomab Tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499.  ASH Annual Meeting Abstracts. 2007;  110 389
• 50 Solal-Celigny P, Roy P, Colombat P. et al . Follicular lymphoma international prognostic index.  Blood. 2004;  104 1258-1265
• 51 The Non-Hodgkin’s Lymphoma Classification P. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma.  Blood. 1997;  89 3909-3918
• 52 Tilly H, Dreyling M. on behalf of the EGWG . Diffuse large B-cell non-Hodgkin’s lymphoma.  Ann Oncol. 2008;  19 ii67-69
• 53 Tilly H, Lepage E, Coiffier B. et al . Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.  Blood. 2003;  102 4284-4289
• 54 Velasquez W S, Cabanillas F, Salvador P. et al . Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).  Blood. 1988;  71 117-122
• 55 Witzig T E, Gordon L I, Cabanillas F. et al . Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.  J Clin Oncol. 2002;  20 2453-2463
• 56 You J Y, Chi K H, Yang M H. et al . Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma.  Ann Oncol. 2004;  15 618-625